Principal Investigator
Coral Olazagasti
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20250163
Clinical Trial Summary
An open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab as consolidation therapy following chemoradiotherapy in limited-stage small-cell lung cancer (TIGOS-LS)
Phase
Phase II
Funding Agency/Sponsor
Industrial
Disease
Thoracic Oncology
Contact Information
Phone Number
305-243-2647